Mallinckrodt, Silence Theraputics to commercialise RNAi therapeutics

22nd July 2019 Uncategorised 0

The agreement provides Mallinckrodt with an exclusive worldwide license for C3 (SLN500) – a preclinical asset that targets a specific protein in the complement pathway.

More: Mallinckrodt, Silence Theraputics to commercialise RNAi therapeutics
Source: News